This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Escape Rheum: Cracking the Code to Rheumatoid Arthritis Treatment

Escape Rheum: Cracking the Code to Rheumatoid Arthritis Treatment

Format

Slide Lecture Series

Time to Complete

1 hour

Released

August 28, 2019

Expires

August 28, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hours
1.00 / CE for Nurse Practitioners (0.38 pharmacology credit)

Accredited Providers

This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Supporter

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. 

Program Description

This activity is based on a live recorded activity. Many patients with rheumatoid arthritis (RA) do not have their disease adequately controlled, and only a minority achieve consistent remission or low disease activity. This activity is designed to sharpen participants’ understanding of the evolving therapeutic landscape for RA and equip them with forward-thinking, patient-centered communication strategies. Through a combination of a mechanism of action (MOA) video, TED Talks-style presentations, a clinical case study, and participants will explore MOAs of targeted therapies, the latest evidence on clinical efficacy and safety of JAK inhibitors, disease activity measures to guide treatment decisions, and use of decision aids.

Intended Audience

The target audience for this educational activity is rheumatologists and NP/PA rheumatology providers. Other healthcare professionals who treat patients with RA may also benefit from participation.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Explain the MOAs of JAK inhibitors in treatment of rheumatoid arthritis (RA).
  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule agents for treatment of RA.
  • Discuss comorbidities that should be considered before starting a patient on a JAK inhibitor.
  • Apply ACR-endorsed RA disease activity measures to guide treatment decisions and evaluate treatment response in patients with RA.
  • Initiate a shared decision-making conversation with patients about treatment goals and options.

Fee Information

There is no fee for this educational activity.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

Faculty

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Sheetal Desai, MD, MSEd
Chief of Rheumatology,
Rheumatology Fellowship Program Director,
Director, Lupus Clinic
Associate Clinical Professor of Medicine,
Division of Rheumatology
University of California, Irvine
Irvine, California

Dr. Desai has nothing to disclose in regards to financial relationship(s) with commercial interests.

Philip J. Mease, MD
Director,
Rheumatology Research Division
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor of Medicine,
University of Washington
Seattle, Washington

Dr. Mease discloses the following:
Consultant: AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Speakers Bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB
Contracted Research: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Accredited Provider Disclosure

Christine Tebben and Marianna Shershneva, MD, PhD, have nothing to disclose in regards to financial relationship(s) with commercial interests.

Planner Disclosures

Planner/Clinical Director for MOA Video (Faculty)
Eric Ruderman, MD
discloses the following:
Consultant: AbbVie, Amgen, Lilly, Novartis, Sandoz, Schipher
Advisory Board: AbbVie, Janssen, Pfizer

Planner (Faculty):
Linda Grinnell-Merrick, MS, NP-BC
discloses the following:
Advisory Board: AbbVie, Novartis, Pfizer, Horizon
Contracted Research: Novartis
Speakers’ Bureau: AbbVie, Celgene, Novartis, Janssen

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing.

Designation Statement

This activity is approved for 1.00 contact hours. Provider Number 6971. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

Credit

1.00

Type

CE for Nurse Practitioners

Accreditation Statement

This activity was planned in accordance with AANP CE Standards and Policies.

Designation Statement

This activity is approved for 1.00 contact hour(s) of continuing education (which includes up to 0.38 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19083821.

Disclosure of Unlabeled Use

This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Christine_Tebben@forefrontcollab.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue